{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008734","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.579343+00:00","generated_at":"2026-06-25T21:44:01.158127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid reports Q1 net loss $16.1M, revenue $1.4M; OV329 IND on track for Q4 2022","bullets":["Net loss $16.1M ($0.23/sh) vs net income $176M in Q1 2021 on one-time Takeda payment.","Revenue fell to $1.4M from $208.4M; current revenue from Marinus and Healx license fees.","Cash and equivalents $166.7M expected to fund pipeline into 2025.","IND for OV329 (GABA aminotransferase inhibitor) planned in Q4 2022 to start Phase 1.","Non-GAAP adjusted operating expenses were $14.2M; total operating expenses $17.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008734","json":"https://secwatch.observer/filing/0000950170-22-008734.json","markdown":"https://secwatch.observer/filing/0000950170-22-008734.md","text":"https://secwatch.observer/filing/0000950170-22-008734.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000095017022008734/0000950170-22-008734-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000095017022008734/ovid-20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:44:01.158127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}